Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.37 |
| ▸ | AOC2 | O75106 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096917 | 0.82 | ALDH1A1 (0.40) | POLBALOX15 | |
| SCHEMBL4090705 | 0.77 | CNR2 (0.44) | HTR4CYP3A4CYP2D6CNR2 | |
| SCHEMBL12204535 | 0.70 | POLB (0.56) | POLBALOX15SYK | |
| SCHEMBL13940799 | 0.70 | CNR2 (0.57) | HTR4CYP3A4CYP2D6CNR2 | |
| SCHEMBL13940797 | 0.70 | CNR2 (0.60) | CYP3A4CYP2D6CNR2 | |
| Hydrochloric Acid SCHEMBL4105426 | 0.69 | CNR2 (0.59) | CYP3A4CYP2D6CNR2 | |
| Hydrochloric Acid SCHEMBL4101816 | 0.69 | CNR2 (0.57) | HTR4CYP3A4CYP2D6CNR2 | |
| SCHEMBL13940826 | 0.69 | CNR2 (0.45) | CYP3A4CYP2D6CNR2 | |
| SCHEMBL13940818 | 0.69 | CNR2 (0.55) | CYP3A4CYP2D6CNR2 | |
| SCHEMBL13940802 | 0.69 | CNR2 (0.61) | CYP3A4CYP2D6CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| US-20090018128-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007088168-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018128-A1 | Compounds | CNR2, CNR1, TRPV1 | POLB 2467/4885ALOX15 280/4885HTR4 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.